Drug Survival of Infliximab and Adalimumab in Inflammatory Bowel Disease

Stay connected! Follow us on X network (Twitter):

Share this content! On (X network) By

Drug Survival of Infliximab and Adalimumab in Inflammatory Bowel Disease Publisher Pubmed

Asadipour E¹ ; Kargar M²

Show Affiliations

1. Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
2. Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran

Source: International Journal of Clinical Pharmacy Published:2020

[No abstract available]

Style	Citing Format
MLA	Asadipour E, Kargar M. "Drug Survival of Infliximab and Adalimumab in Inflammatory Bowel Disease." International Journal of Clinical Pharmacy, vol. 42, no. 6, 2020, pp. 1521-1523.
APA	Asadipour E, Kargar M (2020). Drug Survival of Infliximab and Adalimumab in Inflammatory Bowel Disease. International Journal of Clinical Pharmacy, 42(6), 1521-1523.
Chicago	Asadipour E, Kargar M. "Drug Survival of Infliximab and Adalimumab in Inflammatory Bowel Disease." International Journal of Clinical Pharmacy 42, no. 6 (2020): 1521-1523.
Harvard	Asadipour E, Kargar M (2020) 'Drug Survival of Infliximab and Adalimumab in Inflammatory Bowel Disease', International Journal of Clinical Pharmacy, 42(6), pp. 1521-1523.
Vancouver	Asadipour E, Kargar M. Drug Survival of Infliximab and Adalimumab in Inflammatory Bowel Disease. International Journal of Clinical Pharmacy. 2020;42(6):1521-1523.
BibTex	@article{ author = {Asadipour E and Kargar M}, title = {Drug Survival of Infliximab and Adalimumab in Inflammatory Bowel Disease}, journal = {International Journal of Clinical Pharmacy}, volume = {42}, number = {6}, pages = {1521-1523}, year = {2020} }
RIS	TY - JOUR AU - Asadipour E AU - Kargar M TI - Drug Survival of Infliximab and Adalimumab in Inflammatory Bowel Disease JO - International Journal of Clinical Pharmacy VL - 42 IS - 6 SP - 1521 EP - 1523 PY - 2020 ER -